Thu, Oct 31, 2024
USFDA's VAI classification boosts Cipla’s outlook for niche drug launches, including Abraxane generic
More >
'Diwali Offer' Stocks by Anil Singhvi: Stock markets have been very volatile in last one month. Benchmark equity indices Sensex and Nifty fell in early trade even Thursday i.e. October 31, 2024. Amid this, investors are looking for stocks that can offer good return in long term.
Tue, Oct 29, 2024
Zee Business forecasts indicate a three percent year-on-year revenue increase, with Cipla’s Q2 revenue expected at Rs 6,892 crore, up from Rs 6,678 crore in the same quarter last year
Mon, Aug 01, 2022
Despite healthy Q1FY23 earnings, the pharma major Sun Pharma shares were seen trading flat in the early morning and later declined more than 3 per cent to Rs 913 per share on the BSE intraday on Monday.
Fri, Jul 29, 2022
NTPC Q1 Results FY2023: State-owned NTPC on Friday posted a more than 15 per cent increase in consolidated net profit to Rs 3,977.77 crore in the June quarter on the back of higher income
Fri, Jul 22, 2022
Global Brokerage report on pharma stocks of this week. In this video know the full list and target price to make a buy choice.
Tue, Jun 28, 2022
Pharma company Cipla has agreed to acquire an additional stake for nearly Rs 26 crore in digital tech company GoApptiv Private to raise its shareholding to 22.02 per cent, the company said on Monday.
Mon, Jun 06, 2022
Indian markets on Monday made a gap-down opening as Nifty opened below 16550 levels and Sensex slipped over 100 points. Whereas Nifty Midcap 100 also declined by 0.1 per cent at open.
Wed, May 11, 2022
Cipla Share Price:Brokerages are bullish on the Cipla shares and expects a 28 per cent upside in this stock. A healthy March quarter results will likely act as a trigger for the upside, they opined.
Tue, May 10, 2022
Cipla Q4 results 2022: Drug major Cipla on Tuesday said its consolidated profit after tax declined by 12 per cent to Rs 362 crore for the fourth quarter ended March 2022
Mon, May 09, 2022
Pharma major Cipla's will announce its fourth-quarter results on Tuesday. Senior Research Analyst at Zee Business Kushal Gupta's brings his earnings estimates in this report.
Tomorrow the results of Nifty company Cipla are going to come. How will be Cipla's results in Q4? How will Cipla perform? Know the prediction of the results from Kushal Gupta.
Thu, Mar 31, 2022
The National Pharma Pricing Authority (NPPA) has approved 10.8% hike in over 800 essential drugs starting April 1,2022. This is the biggest hike by NPPA in the last 10 years.
Wed, Mar 30, 2022
Directorate General of GST Intelligence (DGGI) which works under the aegis of the Ministry of Finance has taken action against many big pharma companies in the country for not filing Goods and Services Tax (GST). The pharma giants included are Dr. Reddys Laboratories, Glenmark, Aurobindo Pharma, Mylan and Cipla, as reported by Zee Business’s Tarun Sharma.
Mon, Mar 14, 2022
Several brokerages are betting big on Cipla Limited stocks on the back of robust fundamentals, strong product pipeline in US and improved business outlook. They see an upside of up to 15 per cent in the stock price and find the current valuations attractive.
The recent rally despite muted global cues resulted in a breakout which puts Cipla on buyers' radar.
Mon, Feb 28, 2022
The total equity market capitalisation (m-cap) has dropped to a six-month low of Rs 2,52,39,045.09 crore in February 2022.
Thu, Jan 27, 2022
Brokerage house ICICI Securities and HDFC securities have maintained buy rating on Cipla despite the pharma major witnessed marginal decline in net profit.
Indian market is likely to retest crucial support levels on Thursday, tracking weak global cues
Wed, Jan 26, 2022
Drug major Cipla on Wednesday said Naina Lal Kidwai has resigned as independent director on its board, with effect from March 31, 2022
Tue, Jan 25, 2022
Most of the analysts had estimated that the profit would show a dip year-on-year YoY, and revenue may jump marginally by around 2 per cent.
Mon, Jan 24, 2022
The pharmaceutical major Cipla is likely to report muted third quarter earnings for the financial year 2021-22, most of the brokerage houses and analysts predict in their results preview.
The Indian markets are likely to witness some volatility on Monday tracking weak global cues, but there will be stock-specific action in which global brokerage came out with their reports on business development, or earnings outlook.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
